Rank the most well-adapted cancer treatments
CureMatch provides a scored and ranked listing of the most well-adapted personalized medicine treatment options. The comprehensive analysis considers commonly used treatments, as well as targeted therapy, immunotherapy, hormone therapy, and newly approved oncology drugs. These options are presented either alone (monotherapy) or in combinations of up to 4 drugs.

Filter out therapies that are expected to have poor outcomes
Many cancer treatments are ineffective and can lead to drug resistance, added cost, and side-effects. CureMatch can rank therapies against its databases of genes, pathways, and drug characteristics to predict which therapies are associated with improved outcomes.

Input your own combination therapy options
Combination therapy has been used widely to treat other diseases such as HIV/AIDS, and recent studies have shown it to be effective in cancer. However, its adoption has been limited in cancer in a large part due to its complexity. CureMatch helps you see where your own proposed combinations rank alongside other highly ranked options.


You upload patient molecular profile.

Molecular profiling unique to each patient’s cancer, available through your in-house or 3rd party laboratory, is necessary for the CureMatch analysis. Upload this profiling report through the secure and user-friendly CureMatch cloud-based platform.

We run CureMatch database analysis.

CureMatch uses proprietary algorithms to analyze the genetic information embedded in the patient molecular profile and compare it with our large database of information from medical experts, other patients, clinical trials, and published data.

We rank the top personalized treatments.

Factoring in millions of drug combinations, cancer treatment results and CureMatch analysis, our clinical team generates a report ranking the top personalized treatment options for your patient.

You choose a treatment plan for your patient.

Review the CureMatch report and recommend a treatment plan for your patient using the latest targeted treatments available today.




Performs the multi-parametric analyses required to analyze millions of combination options.

Platform incorporates custom curated databases of publications, clinical trials, genes, pathways, and drug characteristics.

Looks at a patient’s mutations together rather than individually, such that it can analyze options that target multiple mutations rather than single drug therapies targeting individual mutations.

Integration spans many types of biological data.

Agnostic to tumor profiling company data.


Track Record

The CureMatch approach has been used on thousands of patients since its initial development at the UC San Diego Moores Cancer Center and San Diego Supercomputer Center. Some recent Case Studies are provided.


Cross-disciplinary Expertise

The CureMatch approach has been built upon a foundation of discoveries in oncology, genomics, molecular biology, and many other cross-disciplinary fields. Key Publications are provided.


  • "CureMatch offers a superior genomic matching product including customized combination therapy options for informing treatment choices. The numerical score values are a powerful way to help one choose amongst possible clinical interventions."

    Rick Lanman, MD Former Global Chief Medical Officer, Guardant Health, Inc.
  • “CureMatch decision support has been very helpful. I have used it with my patients and it has changed my therapy decisions.”
    John S. Link, MD Memorial Care
  • "Accurate matching of large NGS datasets to clinical application requires a tool that can not only match DNA alteration to drugs, but also a tool that provides mutations desensitizing data as well as synergist combinations of multiple variants. To date, CureMatch is the only tool that provides us this data"
    Alex Rolland Chief Scientist, Founding Member of CTOAM Inc and Liquid biopsy Labs Inc.
  • "CureMatch is where molecular science meets Al to revolutionize cancer care. CureMatch can provide objective cutting-edge information to drive and potentially alter treatment decisions in the space of precision oncology!"
    Nader Javadi, MD Hope Health Center
  • "For too long, we have matched patients to therapies with technologies and criteria more suited to the past than the present. CureMatch is a pioneer in bringing the future of therapy matching to patients today."
    Greg Simon Cancer Moonshot
  • "The future of cancer care will rely upon personalization and precision. But, with the CureMatch approach for designing individualized cancer treatment regimens, the future is now."
    Jason Sicklick, MD, FACS UC San Diego Health
  • "Translation of molecular data into actionable insights is a formidable task. By considering the molecular profile and physician's treatment choices, CureMatch offers a new way to streamline clinical decisions."
    Samantha Hasenleithner Medical University of Graz
  • "CureMatch has been an important part of the decision-making for cancer care, especially for the patients with complexed molecular profiling results."
    Shumei Kato, MD UC San Diego Health
  • "CureMatch is doing what makes sense in getting the right drugs to the right patients. Their therapy options with scores and targeting rationale allows oncologists to make quicker personalized treatment choices"
    Jacob Adoshek, DO Johns Hopkins Hospital
  • The CureMatch report provided me with clarity about therapeutic options for my patients with metastatic cancer given that there are no clinical trials currently available at ours or other regional centers that they would be eligible for.
    Himabindu Gaddipati, MD Clinical Oncologist, Geneticist and Entrepreneur
  • "CureMatch does what no human can do in their head. They computationally permutate millions of drug combinations based on a tumor’s known molecular signature. The rank-ordering of best 3-, 2-, and single-drug combinations gives rational choices to treating oncologists. CureMatch considers biomarkers regardless of the tumor type and line of therapy to strictly match drug mechanisms of action to a tumor’s exact, known molecular profile. This opens up many more treatment options beyond the standard of care - and this is so important when those treatments are failing the patient. CureMatch turns the clinically “non-actionable” information in a typical biomarker test report into “Actionable,” giving much-needed hope to patients."
    Kimary Kulig, PhD, MPH
  • "A CureMatch Report is the dream of any oncologist. It addresses one of the pushbacks whenever we send an NGS report to an oncologist."
    Lior Soussangutman, Ph.D.


Most cancers harbor a cocktail of genomic alterations or mutations. Personalized medicine has typically focused on targeting what the oncologist considers to be the most important mutation, using a single “targeted” drug.

CureMatch is unique in that it looks at all of a patient’s mutations together rather than individually. This enables drug combination recommendations targeting multiple mutations rather than single drug therapies.

CureMatch also integrates multiple types of biological results (DNA sequencing, protein expression, etc.) into its comprehensive analysis, and considers commonly-used cancer treatments as well all of the latest advances in cancer care, including immunotherapy, targeted therapy, hormone therapy, and newly approved cancer drugs.

The resulting analysis ranks the top 2-, 3-, and 4- drug combinations (out of more than 4.5 million options) that are customized for each individual patient.

The analysis is not a substitute for a physician’s decision, but rather it empowers the physician to make the most informed decision, using the most advanced personalized treatment options. The clear analysis layout and ranking is designed to provide actionable knowledge and insight to the oncologist.